TAG:
ivd/lab informatics
Astorg Makes Billion-Dollar Bet on Microbiology Testing
By Janette Wider | From the Volume XXXIII, No. 7 – May 26, 2026 Issue
Thermo Fisher Scientific has agreed to sell its microbiology business to European private equity firm Astorg in a deal valued at $1.075 billion. The transaction, announced in April, includes $1.025 billion in cash and a $50 million seller note. It is expected to …
Payers Unleash AI to Dissect Outlier Billing Patterns
By Janette Wider | From the Volume XXXIII, No. 6 – May 04, 2026 Issue
Diagnostic laboratories can follow every clinical guideline, employ the most talented clinical lab professionals, and provide life-saving data to patients, yet still find themselves in the crosshairs of a federal or payer audit. The culprit is …
For IVD Companies, Tariff Refunds May Be a Long Haul
By Mark Terry | From the Volume XXXIII, No. 5 – April 13, 2026 Issue
Following the US Supreme Court’s decision declaring certain tariffs illegal, the diagnostics industry has entered a murky period regarding potential refunds. For in vitro diagnostics (IVD) manufacturers who paid these tariffs under policies f…
In Earnings Calls, Execs at Quest and Labcorp Push for RESULTS Act
By Mark Terry | From the Volume XXXIII, No. 4 – March 23, 2026 Issue
Chief executives at Labcorp and Quest Diagnostics made it clear during recent investor calls that they want Congress to pass the RESULTS Act. The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act is seen b…
Global IVD Woes in China Should Resonate with US Labs
By Mark Terry | From the Volume XXXIII, No. 3 – March 2, 2026 Issue
In vitro diagnostics (IVD) companies reported a mix of overall growth, with many noting continuing challenges in their diagnostics divisions for recent quarterly financial results. Thermo Fisher Scientific, QuidelOrtho, and Danaher reported the…
Boosting Path Revenue with POC Services
By Stephen Beale | From the Volume XXXIII, No. 2 – February 9, 2026 Issue
CEO SUMMARY: The concept sounds simple—bring mobile point-of-care pathology services to physician offices and ambulatory surgical centers via specially equipped vehicles. Doctors Pathology Services explains some of the road bumps it hit along the way while also uncoverin…
FDA Reviews Oncology Companion Diagnostics
By Janette Wider | From the Volume XXXIII, No. 1 – January 19, 2026 Issue
CEO SUMMARY: Regulatory attorneys indicate that the FDA’s move to reclassify oncology companion diagnostics to Class II medical devices could speed approvals and reduce costs for submissions. From a business perspective, the proposal could allow clinical laboratories to …
Strategies to Succeed with Laboratory Outreach Programs
By Stephen Beale | From the Volume XXXII, No. 18 – December 29, 2025 Issue
In recent years Labcorp and Quest Diagnostics went on buying sprees, acquiring laboratory outreach businesses from major health systems. They argue that they can run these operations more efficiently, while the sellers get much-needed cash infusions. (See …
Quest, Labcorp Tout Their Alzheimer’s Tests and Use of AI
By Mark Terry | From the Volume XXXII, No. 17 – December 8, 2025 Issue
Executives at Quest Diagnostics and Labcorp cheered strong revenue growth in the third quarter. Both companies noted excellent recent launches of Alzheimer’s disease tests. In addition, both companies reported they are leaning heavily into artificial intelligen…
Reforms in China Affect IVD Companies’ Q3 2025 Earnings
By Mark Terry | From the Volume XXXII, No. 16 – November 17, 2025 Issue
Most of the in vitro diagnostics (IVD) manufacturers that serve clinical laboratories worldwide reported facing financial “headwinds” in the China IVD market that affected their third-quarter performance. This was due to policy changes in the country…
CURRENT ISSUE
Volume XXXIII, No. 7 – May 26, 2026
Momentum is building on Capitol Hill to pass the RESULTS Act, which would stave off drastic 15% reimbursement cuts under PAMA. Advocates seek lobbying help from clinical labs and anatomic pathology practices. Also, The Dark Report examines Roche’s deal to acquire PathAI.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized